Does Anesthesia Technique Impact on the Long-term Outcome 5 and 10 Years After the First Intervention in Primary Breast Cancer Surgery? A Follow-up Analysis.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07689253

Acronym

CTC follow up

Enrollment

161

Registered

2026-07-08

Start date

2025-09-01

Completion date

2026-04-30

Last updated

2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Females, Circulating Tumor Cells.Breast, Follow Up Analysis

Keywords

Circulating Tumor Cells, Follow Up Study

Brief summary

Goal of this observational study is to analyze data about cancer recurrence rates 5 and 10 years after primary breast cancer surgery with propofol or sevoflurane anesthesia. Only patients who were enrolled in the primary interventional trial can participate.

Detailed description

It has been assumed that the type of general anesthesia impacts the release of circulating tumor cells (CTC) in the perioperative setting of breast cancer surgery. Those CTC are suspected to promote metastasis formation. We have already investigated the direct effect of sevoflurane vs. propofol on CTC in a randomized controlled trial. There was no significant difference in the number of CTC between the two treatment groups up to 72 hours after anesthesia. CTC are a surrogate marker for cancer recurrence. Therefore, the role of the choice of the general anesthetic for breast cancer surgery should be clarified focusing on the long-term clinical outcome. In this follow-up study, we aim at defining the cancer recurrence and overall survival in patients of the sevoflurane and propofol group of the primary clinical trial.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Only patients who consented and participated in the trial CEC N° 2016 - 01791 can be enrolled. * GC must be available for patients with follow-up consultations at USZ. * For patients with follow-up consultations outside of the USZ for those with unknown GC status, and for those who declined the GC, a study-specific written informed consent must be obtained, which will allow the research team to contact the responsible physician

Exclusion criteria

* Declined study-specific informed consent * Inability to provide study-specific consent

Design outcomes

Primary

Measure	Time frame	Description
Primary co-outcomes are defined as overall survival and disease-free survival.	5 and 10 years after first enrollement	A 5- and 10-year follow-up will be performed for all patients participating in the initial study. In this follow-up, we aim to show both groups' cancer recurrence rates and survival curves 5 and 10 years after surgery.

Countries

Switzerland

Contacts

PRINCIPAL_INVESTIGATORMartin Schläpfer, Prof. Dr. med. M.Sc.

University of Zurich

STUDY_CHAIRBeatrice Beck Schimmer, Prof. Dr. med